We read with interest the report by Rath and Tripathi 1 in which they have evaluated the levels of serum vascular endothelial growth factor (VEGF) and soluble VEFR receptor type 2 in hypertensive disorders of pregnancy. Their findings are certainly intriguing. First, they found increased VEGF levels in pre-eclampsia (PE) and eclampsia. This is contrary to what has been noted in almost all published reports that show reduced VEGF levels. [2] [3] [4] [5] In our investigations, we have consistently found circulating VEGF levels to be undetectable in PE/eclampsia. The basis for this reduction is also well defined. There is ample evidence to prove that circulating VEGF as well as placental growth factor (PlGF) are bound to the excess soluble fms-like tyrosine kinase-1 (sFlt-1) or sVEGFR-1 that is produced by the preeclamptic placenta. 2 There is a close relationship between the elevated sFlt-1 and the reduction in VEGF and PlGF. The authors have not discussed this major difference between published reports and their findings. It is unclear whether the kit used in their study measured free or total (free as well as that bound to sFLt-1) VEGF. If it measures both forms of VEGF, then the total levels could be elevated. 3 This distinction is critical, however, as it is only the free VEGF that is biologically available. Interestingly, their explanation of the reduced sVEGRF2 level is based on the premise that this reflects receptor downregulation as a result of excess VEGF.
Also of interest is their decision to evaluate sVEGFR2 as a diagnostic marker. The hypothesis behind the utility of this molecule as a diagnostic marker is unclear. In contrast the biological basis behind alterations in sFlt-1 in PE has been well studied. A large number of studies, both experimental and human, have shown consistent increases in sFlt-1 in PE, and have suggested using it either alone or in combination with serum PlGF (as sFlt-1:PlGF ratio) to differentiate PE from other hypertensive disorders of pregnancy. 2, 5, 6 Several studies have shown that these possess superior discriminatory ability than that shown by the authors. 5, 7, 8 In a comparative study of pre-eclamptic and normotensive pregnancies, we found the circulating sFlt-1 to be significantly increased in PE compared with normotensive pregnancies, 9 whereas the mean PlGF levels were reduced. Receiver operating characteristic curve analysis showed that sFlt-1 and sFlt-1:PlGF ratio cutoffs of 15.7 and 92.2 ng ml À1 , respectively, were able to distinguish PE from normotensive pregnancies with 100% sensitivity and specificity. PlGF alone had a slightly lower performance (cutoff 177.1 pg ml À1 ; AUC ¼ 98.3%; 95% CI 96.9-99.7). Apart from the fact that the findings are difficult to understand, some conclusions made in the paper seem to be overinterpretation of findings. These include suggestions of a 'role' for sVEGFR2 in the pathogenesis of PE, and that sVEGFR2 reflects endothelial health or endothelial progenitor cell regenerative ability. It is difficult to find the biological significance of the alterations in the sVEGFR-2 levels observed by the authors. As they have themselves noted, the literature on this topic is quite sparse and unclear. As long as this observation is not explained on a sound pathophysiological basis, to suggest the use of this molecule as a test to differentiate different hypertensive disorders of pregnancy seems an overstatement.
